HBeAg-negative chronic hepatitis B: Why do I treat my patients with nucleos(t)ide analogues

Liver International

Volumn 29, Issue SUPPL. 1, 2009, Pages 130-132

  Lampertico, Pietro ^a   Colombo, Massimo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Chronic hepatitis; HBV DNA; Nucleos(t)ide analogue; Resistance

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; TELBIVUDINE; TENOFOVIR;

ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL RESISTANCE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CREATININE BLOOD LEVEL; CROSS RESISTANCE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERADICATION THERAPY; HEPATITIS B; HUMAN; KIDNEY FAILURE; LIVER DISEASE; LONG TERM CARE; MONOTHERAPY; NEPHROTOXICITY; POLYMERASE CHAIN REACTION; RECOMMENDED DRUG DOSE; RECURRENCE RISK; SEROCONVERSION; SIDE EFFECT; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION;

ADENINE; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; NUCLEOSIDES; PHOSPHONIC ACIDS; PYRIMIDINONES; VIRUS REPLICATION;

EID: 59149092224     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01931.x     Document Type: Conference Paper

References (17)

1. Hadziyannis SJ, Papatheodoridis GV, Dimou E, et al. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32: 847-51.
2. Di Marco V, Marzano A, Lampertico P, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004; 40: 883-91.
3. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-51.
4. Hadziyannis S, Sevastianos V, Rapti IN, et al. Sustained biochemical and virological remission after discontinuation of 4 to 5 years of adefovir dipivoxil (ADV) treatment in HBeAg negative chronic hepatitis B. Hepatology 2006; 44: 231A.
5. Lai CL, Gane E, Hsu CW, et al. Two-year results from the Globe trial in patients with hepatitis B: Greater clinical and antiviral efficacy for telbivudine (LdT) vs. lamivudine. Hepatology 2006; 44: 222A.
6. Di Bisceglie A, Lai CL, Gane E, et al. Telbivudine Globe trial: Maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside-treated hepatitis B patients. Hepatology 2006; 44: 230A.
7. Zeuzem S, Buti M, Gane EJ, et al. Baseline parameters predict both early virologic response and longer term outcomes for telbivudine-treated patients with chronic hepatitis B (The Globe Study). Hepatology 2007; 46: 681A.
8. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-20.
9. Shouval D, Akarca US, Hatzis G, et al. Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg(-) chronic hepatitis B patients (Study ETV-027). J Hepatol 2006; 44: S21.
10. Colonno RJ, Rose RE, Pokornowski K. Four year assessment of ETV resistance in nucleoside-naïve and lamivudine refractory patients. J Hepatol 2007; 46: S294.
11. Marcellin P, Jacobson I, Habersetzer F, et al. Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-negative chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data (study 102). J Hepatol 2008; 48: S26: #57.
12. Papatheodoridis GV, Dimou E, Dimakopoulos K, et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005; 42: 121-9.
13. Lampertico P, ViganòM, Manenti E, et al. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005; 42: 1414-9.
14. Rapti I, Dimou E, Mitsoula P, et al. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007; 45: 307-13.
15. Lampertico P, Marzano A, Levrero M, et al. Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative chronic hepatitis B. J Hepatol 2007; 46: S191.
16. Lampertico P, ViganòM, Manenti E, et al. Low resistance to adefovir combined with lamivudine: A 3-year study of 145 lamivudine resistant hepatitis B patients. Gastroenterology 2007; 133: 1445-51.
17. Iavarone M, Lampertico P, Vigano M. Six years of on demand LAM±ADV combination therapy significantly reduces the development and progression of esophageal varices in patients with HBeAg-negative cirrhosis. J Hepatol 2007; 46: S189.